ELI LILLY | 29,763 Euro | -0,013 -0,04 % | |
| WKN: 858560 ISIN: US5324571083 Ticker-Symbol: LLY | Frankfurt | 10.02.12 | 18:44 Uhr |
Branche PharmaAktienmarkt S&P 500 |
|
| ||||||||||||||
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 10.02. | XETR DIVIDEND INFORMATION - 13.02.2012 - 1 | 88 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 10.02.2012 CUM DIVIDENDE UND AM 13.02.2012 EX DIVIDENDE GEHANDELT. THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 10.02.2012. THE EX-DIVIDEND DAY WILL BE 13.02.2012.... Mehr lesen zu: XETR DIVIDEND INFORMATION - 13.02.2012 - 1 | ||||
| 10.02. | XFRA DIVIDEND INFORMATION - 13.02.2012 - 1 | 592 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 10.02.2012 CUM DIVIDENDE UND AM 13.02.2012 EX DIVIDENDE GEHANDELT. THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 10.02.2012. THE EX-DIVIDEND DAY WILL BE 13.02.2012.... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 13.02.2012 - 1 | ||||
| 09.02. | Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co. | 14 | MarketWire | |
| HONG KONG -- (Marketwire) -- 02/09/12 -- This morning, www.MarketFoundations.com announced new reports highlighting VIVUS, Inc. (NASDAQ: VVUS) and Eli Lilly & Co. (NYSE: LLY). Free research downloads... Mehr lesen zu: Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co. | ||||
| 09.02. | Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys | 7 | PR Newswire | |
| INDIANAPOLIS, Feb. 9, 2012 /PRNewswire/ --Get your canvases, paintbrushes and cameras ready - the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer... Mehr lesen zu: Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys | ||||
| 09.02. | Eli Lilly signs licensing deal with Bend Research | 2 | Pharma Bus Review | |
| 08.02. | Bend Research Signs License Agreement With Eli Lilly and Company | 29 | PR Newswire | |
| BEND, Ore., Feb. 8, 2012 /PRNewswire/ --Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, announced today that it has entered... Mehr lesen zu: Bend Research Signs License Agreement With Eli Lilly and Company | ||||
| 07.02. | Eli Lilly: Dividend Total Return Analysis | 1 | Seeking Alpha | |
| 07.02. | Eli Lilly Reveals Positive Outcome From BPH Drug Cialis Study | 103 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) Tuesday said Cialis
improved urinary symptoms and erectile dysfunction in a study of the drug in
parallel with Tamsulosin in men with signs... Mehr lesen zu: Eli Lilly Reveals Positive Outcome From BPH Drug Cialis Study | ||||
| 07.02. | Lilly Recognized as a Top Company for Executive Women | 26 | PR Newswire | |
| INDIANAPOLIS, Feb. 7, 2012 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) has earned a place on the NAFE "Top Companies for Executive Women" list for the fourth consecutive year.
The 2012 list... Mehr lesen zu: Lilly Recognized as a Top Company for Executive Women | ||||
| 07.02. | The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca | 61 | PR Newswire | |
| CHICAGO, Feb. 7, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting... Mehr lesen zu: The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca | ||||
| 07.02. | Eli Lilly Says Phase III Study Of Cialis Meets Primary Endpoint | 36 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - Eli Lilly & Co (LLY) Tuesday announced that a Phase
III study showed both Cialis and tamsulosin significantly improved scores on the
International Prostate Symptom... Mehr lesen zu: Eli Lilly Says Phase III Study Of Cialis Meets Primary Endpoint | ||||
| 07.02. | Lilly (Eli) & Co: New Study Evaluates Cialis® in parallel with T... | 1 | InvestEgate | |
| 07.02. | LILLY (ELI) & COMPANY - New Study Evaluates Cialis® in parallel with Tamsulosin | 24 | PR Newswire | |
| Date: February 7, 2012
For Release: IMMEDIATELY
Refer to: Teresa Shewman, (317) 433-1888 (office), (317) 292-8940 (mobile),
shewmante@lilly.com
... Mehr lesen zu: LILLY (ELI) & COMPANY - New Study Evaluates Cialis® in parallel with Tamsulosin | ||||
| 07.02. | European Urology Shows Eli Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH | 1 | StreetInsider.com | |
| 07.02. | Amylin takes 4Q loss as Lilly partnership ends | 7 | Yahoo-USA | |
| 06.02. | 1 Reason Eli Lilly Looks Weak | 1 | Motley Fool | |
| 06.02. | The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company | 86 | PR Newswire | |
| CHICAGO, Feb. 6, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events... Mehr lesen zu: The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company | ||||
| 06.02. | Eli Lilly Freezes Salaries as Sales Slip for Best-Selling Drug | 3 | Business Week | |
| 04.02. | Eli Lilly To Freeze Salaries For Most Employees In 2012 | 317 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - In a preliminary proxy statement filed Friday with
the U.S. Securities and Exchange Commission, Drug maker Eli Lilly & Co. (LLY)
said that it will freeze salaries... Mehr lesen zu: Eli Lilly To Freeze Salaries For Most Employees In 2012 | ||||
| 02.02. | Eli Lilly Bearish Moving Average Crossover Alert | 1 | SmarTrend | |
| Unternehmen / Aktien | Branche | Aktienkurs | Top-Nachrichten | |
|---|---|---|---|---|
| PFIZER INC | Pharma | +0,59 % | Amgen To Near $100, Outperforming Pfizer | |
| NOVARTIS AG | Pharma | -0,26 % | Ethos bei Novartis gegen Wiederwahl von zwei VR | |
| GLAXOSMITHKLINE PLC | Pharma | +0,24 % | WestLB belässt GlaxoSmithKline auf 'Add' - Ziel 1.520 Pence | |
| ROCHE HOLDING AG | Pharma | -0,19 % | Roche: Illumina schlägt Offerte aus | |
| SANOFI SA | Pharma | -0,04 % | Ukraine to produce diphtheria vaccine using Sanofi Pasteur technology |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
